Megan Kinzel

Calgary, AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Interleukin-33: A new frontier in cancer immunotherapy.

Interleukin-33: A new frontier in cancer immunotherapy.

Journal: International review of cell and molecular biology

Published: May 20, 2026

Population Pharmacokinetics and Optimal Exposure of Antithymocyte Globulin in Myeloablative Hematopoietic Cell Transplantation.

Population Pharmacokinetics and Optimal Exposure of Antithymocyte Globulin in Myeloablative Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: October 30, 2025

Population pharmacokinetics and optimal exposure of anti-thymocyte globulin in myeloablative hematopoietic cell transplantation.

Population pharmacokinetics and optimal exposure of anti-thymocyte globulin in myeloablative hematopoietic cell transplantation.

Journal: Transplantation and cellular therapy

Published: October 30, 2025

Development and computational analysis of high dimensional spectral flow cytometry data for the resolution of innate lymphoid cells in the mammary tumor microenvironment.

Development and computational analysis of high dimensional spectral flow cytometry data for the resolution of innate lymphoid cells in the mammary tumor microenvironment.

Journal: Frontiers in immunology

Published: October 22, 2025

Feeling exhausted, no longer - macrophages keep type 2 innate lymphoid cells energized.

Feeling exhausted, no longer - macrophages keep type 2 innate lymphoid cells energized.

Journal: Cellular & molecular immunology

Published: September 30, 2025

Cytokines Induced by Antithymocyte Globulin in Transplantation Conditioning and Associated Infusional Side Effects.

Cytokines Induced by Antithymocyte Globulin in Transplantation Conditioning and Associated Infusional Side Effects.

Journal: Transplantation and cellular therapy

Published: May 23, 2025

ILC2s in cancer: good, bad, or stay tuned?

ILC2s in cancer: good, bad, or stay tuned?

Journal: Trends in molecular medicine

Published: April 01, 2025

Impact of Underlying Disease and Total Body Irradiation on the Incidence of Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

Impact of Underlying Disease and Total Body Irradiation on the Incidence of Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: July 12, 2024

Targeting Potential of Innate Lymphoid Cells in Melanoma and Other Cancers.

Targeting Potential of Innate Lymphoid Cells in Melanoma and Other Cancers.

Journal: Pharmaceutics

Published: June 13, 2023

Lack of both donor and recipient anti-EBV T cells in EBV seronegative recipients of grafts from seropositive donors.

Lack of both donor and recipient anti-EBV T cells in EBV seronegative recipients of grafts from seropositive donors.

Journal: Bone marrow transplantation

Published: September 15, 2022

Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder.

Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder.

Journal: Transplantation and cellular therapy

Published: September 07, 2022

Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease.

Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease.

Journal: Cytotherapy

Published: April 05, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026